Harvard Apparatus Regenerative Technology Announces $5 Million Financing to Continue Clinical Trial
August 26, 2024 14:36 ET
|
Harvard Apparatus Regenerative Technology, Inc.
Holliston, MA, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage...
Harvard Apparatus Regenerative Technology Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 13, 2024 16:45 ET
|
Harvard Apparatus Regenerative Technology, Inc.
Entered into securities purchase agreements with accredited investors for a $1.5 million private investment in public equity (PIPE) financing. The transaction closed on April 15, 2024.Received $0.5...
Harvard Apparatus Regenerative Technology Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
April 02, 2024 14:36 ET
|
Harvard Apparatus Regenerative Technology, Inc.
Established a Research Collaboration with the McGowan Institute for Regenerative Medicine at the University of Pittsburgh to Study the Repair and Regeneration of the Colon following...
Harvard Apparatus Regenerative Technology and the McGowan Institute for Regenerative Medicine at the University of Pittsburgh Establish a Research Collaboration to Study the Repair and Regeneration of the Colon following Colectomy
December 18, 2023 09:00 ET
|
Harvard Apparatus Regenerative Technology, Inc.
Holliston, MA, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage...